Day: February 17, 2026

PERTH, Australia, Feb. 17, 2026 (GLOBE NEWSWIRE) — Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQB: NSRPF) is pleased to announce the release of its updated corporate presentation, now available on the Company’s website. The new presentation outlines Novo’s strategic priorities, exploration results, project advancements, and near-term catalysts. It offers investors a clear and current view of Novo’s evolving growth strategy and its portfolio of high-potential gold assets. “Our updated corporate presentation reflects the significant progress we’ve made across our exploration portfolio,” said Mr. Michael Spreadborough, Executive Co-Chairman and acting CEO of Novo Resources. “As we continue to unlock value across our projects, we remain focused on delivering disciplined growth and long-term value for shareholders.”The...

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Feb. 17, 2026 (GLOBE NEWSWIRE) — SHARC International Systems Inc. (CSE: SHRC) (FSE: IWIA) (OTCQB: INTWF) (“SHARC Energy” or the “Company”) would like to announce its intention to complete a non-brokered private placement of unsecured convertible debentures (each, a “Debenture”) with a principal amount of up to $2,000,000 (the “Offering”). The Offering will include an up to 25% over-allotment option, exercisable by the Company, which equates to an additional $500,000 (“Greenshoe”). If fully exercised, the total proceeds of the Offering will be gross proceeds of $2,500,000. The Debentures will bear interest at a rate of 8.0% per annum calculated annually and paid on maturity and will...

TORONTO, Feb. 17, 2026 (GLOBE NEWSWIRE) — Constellation Software Inc. (TSX:CSU) announced today it will host a fourth quarter conference call and live audio webcast on March 10, 2026 at 8:00 a.m. ET. The Company’s quarterly results will be disseminated via press release, and made available on the Company’s website (www.csisoftware.com) and SEDAR+ (www.sedarplus.ca), after the Toronto Stock Exchange closes on Monday, March 9, 2026. Mark Miller, President, Jamal Baksh, Chief Financial Officer, and Bernard Anzarouth, Chief Investment Officer will be available during the March 10, 2026 conference call to answer questions regarding the Company’s results. To access the call, please dial 1-877-879-1183 (North America toll free) or 1-412-902-6703 (International) and using conference ID 8822692.  A conference operator will create a queue...

VANCOUVER, British Columbia, Feb. 17, 2026 (GLOBE NEWSWIRE) — Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) (“Teck”) President and Chief Executive Officer Jonathan Price, will be presenting at the BMO Global Metals, Mining & Critical Minerals conference on Monday, February 23, 2026, at 1:30 p.m. Eastern/10:30 a.m. Pacific time. The investor presentation will include information on company strategy, financial performance, and outlook for the company’s business units. The presentation will be webcast through the following link at: https://app.webinar.net/PNYBpm6JGbj. Alternatively, the webcast with supporting slides will be available on Teck’s website at: www.teck.com. About TeckTeck is a leading Canadian resource company focused on responsibly providing metals essential to economic development and the energy transition....

MELBOURNE, Australia and INDIANAPOLIS, Feb. 18, 2026 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has submitted a marketing authorization application (MAA) in Europe for TLX101-Px (O-(2-[18F]fluoroethyl)-L-tyrosine, 18F-FET), its glioma (brain cancer) imaging candidate. Telix has been preparing the European and U.S. regulatory packages for TLX101-Px concurrently, bringing forward the European submission to meet an agreed filing date while aligning with aspects of the U.S. Food and Drug Administration (FDA) package to support the additional application. The submission covers major European markets1. Telix is seeking to expand patient access to advanced brain imaging through a broad clinical label, reflective of current clinical practice guidelines2. Submission of the U.S....